Effects of myo-inositol on glucose variability in women with gestational diabetes.
Effects of myo-inositol on glucose variability in women with gestational diabetes. Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6567-6572 Authors: Pintaudi B, Di Vieste G, Corrado F, Lucisano G, Giunta L, D'Anna R, Di Benedetto A Abstract OBJECTIVE: Myo-inositol supplementation prevents gestational diabetes (GDM) in women at risk and reduces insulin resistance in women with GDM. No data are available about its effect on glucose variability. The aim of this study was to evaluate the effects of a supplementation of myo-inositol on glucose variability in women with GDM. PATIENTS AND METHODS: Myo-inositol effect on glucose variability was studied in a pilot case-control study involving 12 consecutive pregnant women (median age 34 years, 25.0% insulin-treated) with GDM. Six women received myo-inositol 2 g plus 200 mg folic acid twice a day, the others received only folic acid. Information on side effects was collected. A continuous glucose monitoring system was wore before and at the beginning of the supplementation. Mean amplitude of glucose excursion (MAGE), standard deviation (SD) and variability coefficient were the indexes of glucose variability. RESULTS: Myo-inositol lowered glucose levels in the first days after the treatment was started. However, pre-post supplementation overall mean glucose difference was similar between groups (-4.8 vs. 5.0 mg/dL for controls and treated, respectively; p = 0.79). Pre-post differences in SD (13.7 vs. 6.0; p
ConclusionIn KSA, women who developed GDM, particularly those who are older, multigravid, and multiparous and who have a prior history of GDM, are at an increased risk of developing T2DM. Postpartum diabetes screening of patients with GDM within the recommended period need to be improved.
ConclusionsThe results support feasibility and effectiveness of a lifestyle intervention after complicated pregnancies to improve maternal cardiometabolic risk factors. Further randomized controlled studies are needed with longer follow-up to evaluate durability. In the meantime, we suggest health care professionals to offer lifestyle interventions to women after complicated pregnancies.FundingThis study was funded by ZonMW (61200024).
The maternal cardiovascular system undergoes profound changes to support the increasing demands of fetal growth during pregnancy.1 It is well established that pregnancy complications have lifelong implications on the health of the offspring. However, the effect these complications have on the long term health of mothers is less understood.2 An accumulating body of evidence has shown that common pregnancy complications, including, gestational diabetes mellitus, preeclampsia, low birth weight, and preterm delivery,2 can be associated with future cardiovascular adverse events in mothers.
ConclusionsThe observed miscarriage rate was comparable to the background US population rate (15 –20%). Patients treated with insulin experienced a 23% incidence of severe hypoglycemia and lower birth weights were observed in the insulin-treated, GCK-affected neonates. These data support published guidelines of no treatment if the fetus is suspected to have inherited GCK-MODY and highlight th e importance of additional studies to determine optimal pregnancy management for GCK-MODY, particularly among unaffected fetuses.
Conditions: Diabetes Mellitus; Pregnancy Complications Intervention: Drug: Faster-acting Aspart insulin Sponsor: Rigshospitalet, Denmark Not yet recruiting
Discussion Intrauterine growth retardation or fetal growth retardation is due to a pathological process that causes decelerated fetal growth velocity. Small-for-gestational age (SGA) is an infant with growth parameters below the normal range for gestational age. More commonly, SGA is defined as a birth weight
ConclusionThis study has experimentally demonstrated that high daily intake of sugar in healthy pregnancies causes adverse effects on the mother and offspring.
The objective of this study was to use birth records and a combination of statistical and geographic information system (GIS) analyses to evaluate GDM rates among subgroups of pregnant women in Michigan. MATERIALS AND METHODS:: We obtained data on maternal demographic and health-related characteristics and regions of residence from 2013 Michigan birth records. We geocoded (ie, matched to maternal residence) the birth data, calculated proportions of births to women with GDM, and used logistic regression models to determine predictors of GDM. We calculated odds ratios (ORs) from the exponentiated beta statistic of the lo...
In this study, we investigated the role of miRNA in GDM by analyzing miRNA expression profiling in placenta tissues from healthy or GDM pregnancies. We found that miR‐96 was the most down‐regulated miRNA in GDM samples. Furthermore, miRNA target gene p rediction revealed that p21‐activated kinase 1 (PAK1) is a potential target of miR‐96. Functional assays showed that miR‐96 enhanced β‐cell function, whereas PAK1 inhibited β‐cell function and cell viability. Our findings demonstrate that miR‐96 plays a critical role in GDM development by regulating PAK1 expression, insulin secretion, and β‐c...
ConclusionIn KSA, women who developed GDM, particularly those who are older, multigravid, and multiparous and who have a prior history of GDM, are at an increased risk of developing T2DM. Postpartum screening of patients with GDM must be improved.